Clinical Trial Update: An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) [Phase 2]

View source ↗

Summary

A Phase 2 extension study for subjects who received Avalyn's inhaled antifibrotic agent (SAIL) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Progressive Pulmonary Fibrosis

Drugs mentioned

• Avalyn Inhaled Antifibrotic Agent (SAIL)

Snippet

Sponsor: Avalyn Pharma Inc. | Conditions: Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Status: RECRUITING